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Nanotoxicology: in Vitro–in Vivo 
Dosimetry
http://dx.doi.org/10.1289/ehp.1104320
Gangwal et al. (2011) addressed an impor-
tant topic for nanotoxicology about assess-
ing the toxicity of inhaled nano  materials by 
recom  mending relevant concentrations for 
in vitro toxicity testing. Their efforts to select 
in vitro concentrations based on reported 
occupational exposure levels of inhaled 
nano  materials are, indeed, laudable. Their 
under  lying conceptual approach is logical, 
involving a widely used and well-accepted 
particle dosimetry model [multiple-path 
particle dosimetry (MPPD)] to estimate 
deposited and retained mass doses in the 
pulmonary alveolar region of nano  material-
exposed workers. They then expressed these 
doses as per-unit alveolar surface area in 
order to select for in vitro testing the same 
alveolar epithelial cell surface area doses. 
However, while this concept makes good 
sense when applying it to short-term (daily) 
deposited doses, it makes less sense and 
can be highly misleading when the same 
approach is used for doses that have accumu-
lated in the alveo  lar region after long-term 
chronic inhalation exposures of humans. 
Thus, it is unfortunate that the authors made 
it a main point to estimate (although crudely 
and with some questionable assumptions) 
the dose of inhaled nano  materials that is 
retained or accumulated on the pulmonary 
alveolar surface over a full working lifetime 
of 45 years of exposure to 1 mg/m3 airborne 
concentration. Gangwal et al. then converted 
this 45-year accumulated surface area dose 
to an equivalent in vitro concentration (per 
square centi  meter) as a selection criterion 
for in vitro dosing. Under “Concentrations 
recommended for in vitro testing,” they con-
cluded that the long-term retained human 
alveo  lar surface area dose equates to in vitro 
concentrations of 50–68 µg/mL and that 
These amounts for a full working lifetime lie 
within the range of the highest in vitro assay con-
centrations tested in the literature for Ag [silver 
nano  particles] and TiO2 [titanium dioxide nano-
particles] on human, rat, and mouse cell lines. 
(Gangwal et al. 2011)
These are extraordinarily high concentra-
tions, and unfortunately this article may be 
viewed as a justification for using such high 
in vitro dosing uncritically. Gangwal et al. 
(2011) did not discuss anywhere in the arti-
cle the reasoning behind equating lifetime 
accumulated doses with doses that are given 
all at once as a bolus in a short-term in vitro 
system. The difference in dose rate alone—
not considering anything else—spans many 
orders of magnitude. At best, these extrapo-
lated high in vitro concentrations may be 
labeled as the high-end limit of an in vitro 
study using a wide range of doses.
To their credit, Gangwal et al. (2011) 
estimated lung surface area doses achieved 
for a 24-hr exposure to an inhaled concen-
tration of 1 mg/m3 and—as one would 
expect—extrapolated this to much lower 
concentrations of 0.17–0.57 µg/mL for 
equivalent in vitro dosing with TiO2 and 
Ag nano  particles. If they had used a more 
realistic higher value for the human alveolar 
surface area—as they did for the full working 
lifetime exposure—the extrapolated equiva-
lent short-term in vitro concentrations would 
have been even lower by about one order of 
magnitude. Unfortunately, the authors did 
not emphasize the tremendous differences 
between actual high doses used in most pub-
lished in vitro studies of nano  particles and 
the more realistic much lower in vitro doses. 
For in vitro testing, use of a wide range of 
doses, starting at—or even better—below 
the 24-hr inhalation equivalent and increas-
ing to a maximum of the lifetime exposure 
equivalent, could be a practical approach. 
With respect to carbon nano  tubes 
(CNTs), Gangwal et al. (2011) reported 
results only for the full working lifetime 
exposure scenario and the resulting extrapo-
lated equivalent in vitro concentrations. 
According to the authors, these extrapolated 
high equivalent in vitro concentrations are at 
the low end of concentrations that have been 
reported for CNTs in the in vitro literature. 
Implications for selection of realis  tic in vitro 
exposures to CNTs were not discussed, nor 
was the more relevant 24-hr exposure sce-
nario for CNTs modeled to derive an equiv-
alent short-term in vitro dose. This would 
have provided a suggested range of in vitro 
dosing for CNTs as pointed out above for 
Ag and TiO2 nano  particles, provided the 
dosimetry model (MPPD) is applicable for 
CNTs. Unfortunately, the validity of the 
MPPD model for fiber-shaped structures of 
nano    sized dimensions was neither explained 
in sufficient detail by Gangwal et al., nor has 
it been confirmed and published, specifically 
for nano  fibers and nano  tubes. Moreover, 
a thorough literature search reveals that 
CNT aerosols at workplaces are not present 
as individual straight nano  fibers, but occur 
mostly as small and large tangles of differ-
ent shapes of hollow tubes with unknown 
effective density (density is not that of solid 
carbon) (Han et al. 2008; Methner et al. 
2010; Tsai et al. 2009). There is currently 
no deposition model that could be applied 
for such nano  structures without additional 
research to obtain necessary input data.
A careful selection of in vitro doses for 
nano  particle toxicity testing is very important. 
Thus, authors, reviewers, and journal editors 
should be critical when submitting, reviewing, 
and accepting papers for publication.
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We appreciate the letter from Oberdörster 
commenting on the importance of careful 
selection of in vitro doses for nano  material 
(NM) toxicity testing and his assessment of 
our article (Gangwal et al. 2011). Because the 
objective of our study was to use limited data 
on potential human occupational exposure to 
NMs to identify bounding limits for toxic-
ity testing, we believe our conclusions and 
Oberdörster’s views to be generally aligned. 
Our article described how to apply sparse 
NM exposure information from manufactur-
ing and R&D (research and develop  ment) 
settings and relevant particle dosimetry model 
inputs, based on a report of the International 
Commission on Radiological Protection 
(1994), to estimate NM mass retained in the 
alveolar region of the human lung. Modeled 
alveolar lung surface concentrations (micro-
grams per square centimeter) were then used 
to estimate bounding in vitro NM solution 
concentrations (micrograms per milli  liter) 
representative of short-term (24-hr) and long-
term (full occupational lifetime of 45 years) 
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exposure scenarios. In comparing our rough 
“equiva  lent” estimates obtained based on life-
time exposure to concentrations currently 
being used for in vitro testing, we indeed 
intended to highlight that such concentra-
tions represent a high end bounding limit, 
as Oberdörster has emphasized. Equivalent 
in vitro concentrations based on a 24-hr sce-
nario are intended to represent more realistic 
short-term exposures.
We agree with Oberdörster that our article 
(Gangwal et al. 2011) should not be viewed as 
justification for using very high NM in vitro 
testing concentrations. Rather, we demon-
strate the importance of understanding in vitro 
concentrations in the context of the potential 
for human NM exposure to improve study 
design and facilitate interpretation of testing 
results. For NMs currently being tested in 
the U.S. Environmental Protection Agency’s 
(EPA) ToxCast project (Dix et al. 2007), we 
are in fact evaluating multiple concentrations 
based on consideration of potential exposure 
and generally have set NM testing concentra-
tions to range from below the 24-hr inhala-
tion exposure equivalent to the full working 
lifetime equivalent.
As we note in our article (Gangwal 
et al. 2011) and as Oberdörster has further 
emphasized, there are significant uncertain-
ties associated with our estimates of expo-
sure and associated dosing concentrations. 
These include uncertainties associated with 
screening-level tools available for modeling 
deposition of engineered nano  materials and 
with our understanding of charac  teris  tics and 
properties of materials found in the human 
environment. In the interest of mining avail-
able tools to inform design of toxicity tests 
for immediate use, we did opt to make sig-
nificant simplifying assumptions related to 
particle charac  teristics and to apply a version 
of the MPPD model adapted by the develop-
ers for application to nano  fibers/nano  tubes 
(National Institute for Occupational Safety 
and Health 2008). The modeled alveolar 
mass retained for CNTs based on more realis-
tic, short 24-hr inhalation exposure duration 
is available online (U.S. EPA 2011).
One point that Oberdörster missed in 
our article (Gangwal et al. 2011) is that we 
calculated alveolar lung surface concentra-
tion using the same low estimate of human 
alveolar surface area for both the full working 
lifetime and the 24-hr exposure duration, and 
thus calculations for both exposure scenarios 
may be lower by approximately one order of 
magnitude. 
We are pleased that our framework for 
using available exposure information to 
inform selection of in vitro toxicity testing 
concentrations is generating important dis-
cussion. We believe the issues and limitations 
raised in our article and by Oberdörster are 
important and demonstrate a critical need 
for continuing research to understand the 
potential for human exposure to engineered 
nano  materials and to design environ  mentally 
relevant toxicity testing schemes. 
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Bisphenol A in Thermal Paper 
Receipts: An Opportunity for 
Evidence-Based Prevention
http://dx.doi.org/10.1289/ehp.1104004
The recent report by Taylor et al. (2011) on 
the pharmaco  kinetics of bisphenol A (BPA) 
emphasizes the similarities between humans, 
monkeys, and mice in the metabolism of this 
ubiquitous and potentially toxic synthetic 
chemical. The authors suggested that human 
exposure to BPA may be “much higher than 
previously assumed.” They observed that 
a potentially important non  food source of 
exposure to BPA may be the thermal paper 
used in cash register receipts. 
BPA is found in receipt paper (Mendum 
et al. 2010) and appears to transfer read-
ily from receipts to skin (Biedermann et al. 
2010) and to be absorbed trans  dermally 
(Zalko et al. 2011). Retail workers, who likely 
have more frequent exposure to cash receipts 
containing BPA than other Americans, have 
been found to have elevated levels of urinary 
BPA (Lunder et al. 2010). BPA has been 
shown to be capable of crossing the placenta 
(Balakrishnan et al. 2010) and to be toxic dur-
ing early mammalian develop  ment (vom Saal 
and Hughes 2005). This toxicity is rele  vant to 
humans, given the similarities in BPA metab-
olism observed across species by Taylor et al. 
(2011). Prenatal exposure of human infants 
to BPA has been associated with behavioral 
anomalies (Braun et al. 2009).
There is a sense of déjà vu about this story: 
In the 1970s polychlorinated biphenyls (PCBs) 
were widely used in carbonless copy paper 
(Erickson and Kaley 2011). PCBs were shown 
to be absorbed through the skin (Carpenter 
2006), and prenatal exposures to PCBs were 
subsequently shown to cause irreversible brain 
injury to developing fetuses, which resulted in 
permanent loss of IQ (intelli  gence quotient) 
and alterations in behavior (Jacobson and 
Jacobson 1997). This exposure ended when 
the manufacture of PCBs was banned in the 
United States in 1976. 
The research of Taylor et al. (2011) con-
tributes to our understanding of the poten-
tial harms to the developing fetus from 
BPA. These findings under  score the need 
to develop a new U.S. chemical policy that 
would require toxicological testing of widely 
used chemi  cals already on the market and 
pre  market safety testing of all proposed new 
chemicals (Landrigan and Goldman 2011). 
The time to presume that chemicals are safe 
until they are proven beyond all doubt to 
cause injury to America’s children is past. 
While research into the effects of exposure 
to BPA continues, we have an opportunity 
to act today on the basis of the available evi-
dence to remove BPA from thermal paper, 
as we strive to protect the health and future 
intelligence of America’s children.
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